Market Newsdesk

• Successfully completed initial public offering on U.S. Nasdaq in February 2021, raising gross proceeds of $30 million
• Clinical development on track with dosing of first patient in Phase 1/2a melanoma trial of cancer vaccine EVX-02
• Cash reserves of $5.8 million at December 31, 2020 plus funds from IPO provide funding for at least 12 months from the date of completion of the IPO

COPENHAGEN, Denmark, April 06, 2021 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the fourth quarter and full year 2020 financial results and provided an operational update.

Lars Wegner, CEO of Evaxion, said: “Evaxion made outstanding progress in 2020 in redefining the immunotherapy discovery process through our AI platform technologies, despite the complications caused by the COVID-19 pandemic. We are very pleased with the successful initial public offering on U.S. Nasdaq, concluded in February 2021, which raised gross proceeds of $30 million and positions Evaxion for further progress with our patient-specific cancer immunotherapies.”

“In 2020, we initiated a Phase 1/2a clinical trial of the adjuvant immunotherapy EVX-02, in combination with checkpoint inhibitors in patients with advanced melanoma. Both this study and our Phase 1/2a trial with EVX-01 remain on track and our other product candidates – EVX-03 for multiple cancer indications and EVX-B1, a vaccine for prevention of S. aureus – are progressing well through preclinical development.”

“Financially, Evaxion is in a strong position with cash and cash equivalents of $5.8 million at December 31, 2020, to which we have now added the proceeds from our IPO. This provides funding to advance our four product candidates into 2022, covering a number of key expected milestones. These include Phase 1/2a data on EVX-01 and EVX-02 expected in late Q2 2021 and filing for approval of a clinical trial of EVX-03 in multiple cancers in the second half of the year.”

Operational and Business Highlights in 2020

• Dosed first patient in Phase 1/2a melanoma trial of cancer vaccine EVX-02 in combination with checkpoint inhibitors
• Appointed Marianne Søgaard, previously an attorney practicing technology law, including processes to acquire technology solutions, and commercial law, as Chairwoman of the Board of Directors
• Launched new AI powered platform, RAVEN, to enable faster response to emerging viral pandemics
• Partnered with SB3000 for rapid scale up for commercial production of corona virus vaccines with its continuous manufacturing technology
• Publication of an article in Nature Communications showing how deep data on immune complex stability could optimize immunotherapy in cancer

Events after the Reporting Period

• Closed U.S. initial public offering of 3,000,000 American Depositary Shares at a public offering price of $10.00 per ADS. The gross proceeds from the offering, before deducting underwriting fees and commissions and other offering expenses, were $30 million.
• The shares began trading on the Nasdaq Capital Market on February 5, 2021 under the ticker symbol “EVAX”.
• Opened new corporate headquarters and research laboratory facility located in the DTU Science Park in Hoersholm near Copenhagen, Denmark.

Expected milestones in 2021

• Phase 1/2a data on EVX-01 in metastatic melanoma – Q2 2021
• Phase 1/2a data on EVX-02 in adjuvant melanoma – Q2 2021
• Regulatory filing for clinical trial of EVX-03 in multiple cancers – H2 2021

Fourth Quarter and Full Year 2020 Financial Results

• Cash position: As of December 31, 2020, cash and cash equivalents were $5.8 million compared to $9.6 million as of December 31, 2019. On February 9, 2021, we closed our recent IPO raising net proceeds of $27.9 million after underwriting discounts and commissions.
• Research and Development expenses were $10.9 million for the year ended December 31, 2020, compared to $8.2 million for the same period in 2019. The increase of $2.7 million was primarily related to increased spending, net of grant income, for ongoing development on our platform, pre-clinical product candidates, and clinical trials. In addition, employee-related costs increased due to higher headcount.
• General and Administrative expenses were $5.7 million for the year ended December 31, 2020, compared to $2.6 million for the same period in 2019. The increase of $3.1 million was primarily related to increased employee-related costs due to increased headcount and increases in overhead and professional fees related to the expansion of our corporate function for our initial public offering.
• Net loss was $15.0 million for the year ended December 31, 2020 or ($0.97) loss per basic and diluted share, compared to $11.2 million, or ($0.81) loss per basic and diluted share, for the same period in 2019.

Guidance

• Evaxion’s operating plan extends its cash runway into 2022.

Webcast and Conference Call

Evaxion will host a webcast and conference call today, April 6, 2021, at 8.30 a.m. EDT.

To access dial-in details for the conference call, please use the following link:
https://www.incommglobalevents.com/registration/client/7148/evaxion-biotech-q4-and-full-year-2020-earnings-call/

Alternatively to access the webcast, please use the following link:
https://event.on24.com/wcc/r/3083146/DF0AB39A39342E036D397705A664556F

About Evaxion

Evaxion Biotech A/S is an AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Evaxion has developed its AI-immunology core technology to deeply understand the biological processes relevant for engaging the immune system so the Company can harness its powers through novel immunotherapies. Evaxion’s scalable AI-immunology core technology enables broad applicability across diseases with immunological components. With deep insights into the biological processes of the immune system, Evaxion bridges technology, engineering expertise and drug development know-how to bring novel immunotherapies to patients.

For more information
Evaxion Biotech A/S		LifeSci Advisors LLC
Glenn S. Vraniak		Mary-Ann Chang
Chief Financial Officer		Managing Director
[email protected]		[email protected]
+1 (513) 476-2669		+44 7483 284 853

 

Source: Evaxion Biotech

Forward-looking statement

This announcement contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this announcement regarding the Company’s future operations, plans and objectives are forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; risks associated with the Company’s development work; cost and success of the Company’s product development activities and preclinical and clinical trials; risks related to commercializing any approved pharmaceutical product developed using the Company’s AI platform technology, including the rate and degree of market acceptance of the Company’s product candidates; risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture; risks associated with the Company’s inability to enter into partnerships; risks related to government regulation; risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s ADSs and ordinary shares, risks associated with the pandemic caused by the novel coronavirus known as COVID-19 and other risks and uncertainties affecting the Company’s business operations and financial condition.

Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, see the risks described in the “Risk Factors” section included in the Company’s prospectus filed on February 5, 2021 and the Company’s current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this announcement speak only as of the date hereof, and except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Evaxion Biotech A/S
Consolidated Statements of Financial Position Data (Unaudited)
(USD in thousands)
	December 31,
		2020			2019
Cash and cash equivalents	$	5,834		$	9,559
Total assets		11,965			11,084
Total liabilities		4,927			1,722
Share capital		2,648			2,481
Other reserves		31,669			22,693
Accumulated deficit		(27,279)			(15,812)
Total equity		7,038			9,362
Total liabilities and equity	$	11,965		$	11,084

Evaxion Biotech A/S
Consolidated Statements of Comprehensive Loss Data (Unaudited)
(USD in thousands, except per share data)
	Year Ended December 31,
		2020			2019
Research and development expenses	$	10,902		$	8,216
General and administrative expenses		5,666			2,647
Operating loss		(16,568)			(10,863)
Finance income		216			65
Finance expenses		(223)			(1,222)
Net loss before tax		(16,575)			(12,020)
Income taxes		1,557			825
Net loss for the period	$	(15,018)		$	(11,195)
Net loss attributable to equity holders of Evaxion Biotech A/S	$	(15,018)		$	(11,195)
Loss per share – basic and diluted	$	(0.97)		$	(0.81)
Number of shares used for calculation (basic and diluted)		15,434,758			13,892,314

Announces Return to Service with First Voyages Embarking Outside of the U.S. from the Caribbean and Greek Isles on Three Norwegian Cruise Line Ships Beginning July 2021

Company Has Proposed to CDC Plan to Restart Cruising from U.S. Ports Starting July 4

All Initial Voyages to Operate with Robust, Multi-Layered SailSAFE™
 Health and Safety Program Including Mandatory Vaccinations for All Guests and Crew and Universal COVID-19 Testing

Company Announces Formation of its SailSAFE Global Health and Wellness Council

MIAMI, April 06, 2021 (GLOBE NEWSWIRE) — Norwegian Cruise Line Holdings Ltd. (the “Company”) (NYSE: NCLH), a leading global cruise company which operates the Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises brands, today announces a two-pronged plan for its long-awaited return to cruising this summer. The Company unveils its phased cruise resumption for voyages embarking outside of the U.S. with sailings originating in Jamaica, Dominican Republic and Greece beginning in July 2021 with Norwegian Joy, Jade and Gem. In parallel, the Company submitted a proposal to the U.S. Centers for Disease Control and Prevention (“CDC”) on April 5, 2021, outlining its plan to restart cruising from U.S. ports starting July 4 and requesting the CDC lift the Conditional Sail Order. To provide a uniquely safe and healthy vacation experience, all initial voyages will operate with fully vaccinated guests and crew in addition to the Company’s robust, multi-layered SailSAFE™ health and safety program, which includes universal COVID-19 testing prior to embarkation. The Company also announces the formation of the SailSAFE Global Health and Wellness Council (“the Council”), the Company’s expert public health council, chaired by former Commissioner of the U.S. Food and Drug Administration (“FDA”) Dr. Scott Gottlieb, which will complement the work of the Healthy Sail Panel (“HSP”).

“We are excited to unveil our initial plans for the resumption of cruise voyages embarking outside of the U.S. with sailings to the Caribbean and Europe. In addition, we continue to plan for a resumption of cruising from U.S. ports and await further discussion with the CDC regarding our proposal for a July 4 restart to participate in America’s national opening. As we prepare for our return to cruising, the health and safety of our guests, crew and communities we visit is our first priority, as demonstrated by the establishment of our robust, multi-layered SailSAFE health and safety program and our Company’s SailSAFE Global Health and Wellness Council,” said Frank Del Rio, president and chief executive officer of Norwegian Cruise Line Holdings Ltd. “Safe and highly effective vaccines are a gamechanger and to create the safest environment possible, we will require all guests and crew to be vaccinated against COVID-19. Vaccine requirements will be combined with multiple additional layers of protection against COVID-19 introduction, including universal testing, and we will continue to evaluate and modify protocols over time as the science dictates.”

Del Rio continued, “The return to cruising has been much-anticipated by our loyal guests, valued travel partners, the destinations we visit and our team members across the globe. We look forward to once again delivering best in class vacation experiences and also restarting our cruise ecosystem, bringing much needed economic benefit back to our homeports and the destinations we visit that have been significantly impacted by the halt in cruising.”

Resumption of Voyages Embarking Outside of U.S.

As part of the phased return to cruising, Norwegian Cruise Line will initially offer seven-day cruises to the Greek Isles on Norwegian Jade from Athens (Piraeus), Greece beginning July 25, 2021, and seven-day Caribbean itineraries originating in Montego Bay, Jamaica beginning on August 7, 2021 on Norwegian Joy and from La Romana, Dominican Republic on Norwegian Gem beginning August 15, 2021. Certain sailings outside of these newly announced voyages have been cancelled. Impacted guests on voyages that will not operate will be notified accordingly. As Norwegian Cruise Line makes its final preparations to welcome guests on board, guests have the opportunity to follow along with its new docuseries, EMBARK – The Series, premiering April 15 at www.ncl.com/embark and Facebook.

Regent Seven Seas Cruises and Oceania Cruises will announce details on their voyage resumption plans at a future date. All voyages on these brands with embarkation dates through July 31, 2021 have been cancelled. Impacted guests on voyages that will not operate will be notified accordingly.

The Company continues to expect a phased-in approach to reintroducing additional vessels across its three brands while taking into account the public health environment, global travel restrictions and port availability, among other considerations.

SailSAFE Health and Safety Program

The Company is committed to protecting the health and safety of its guests, crew and communities visited and has developed SailSAFE, a robust, multi-layered and science-backed health and safety program in response to COVID-19. The SailSAFE health and safety program will be informed by expert guidance from the HSP and the Council, domestic and international governments and public health agencies. The Company believes that mandatory vaccinations for all guests and crew, combined with universal testing and other preventative measures developed in conjunction with the HSP, will provide a uniquely safe and healthy vacation environment that it believes exceeds all other vacation choices on land and at sea. These measures, including vaccination requirements, will be continuously refined as science, technology and the knowledge of COVID-19 evolves. In addition, guests must comply with all travel requirements of the countries where voyages originate and visit. These requirements may include receiving a negative polymerase chain reaction test (“PCR”) result prior to arriving in the country where the cruise originates, testing upon arrival into the country and the completion of appropriate travel entry forms.

The Company further extended its depth and breadth of experts with the formation of its SailSAFE Global Health and Wellness Council, comprised of six experts at the forefront of their fields and led by Chairman Dr. Scott Gottlieb, former Commissioner of the FDA and Co-Chair of the Healthy Sail Panel. The Council’s work will complement the HSP initiative and will focus on the implementation, compliance with and continuous improvement of health and safety protocols across the Company’s operations. The Council was assembled in mid-2020 and has been advising the Company on the development of its SailSAFE program. Subject matter experts joining Dr. Scott Gottlieb are:

• Dr. Steven Ostroff, MD, former acting commissioner of the FDA and former Deputy Director of the National Center for Infectious Diseases at the CDC.
• Dr. Phyllis Kozarsky, MD, Professor Emerita in Medicine and Infectious Diseases at Emory University, Co-Founder of the International Society of Travel Medicine.
• Caitlin Rivers PhD, Assistant Professor in the Department of Environmental Health and Engineering at the Johns Hopkins Bloomberg School of Public Health.
• Kate Walsh, PhD, Dean of the School of Hotel Administration at Cornell University.
• John Mason, CEO and Chairman of The Sabre Companies with extensive experience in developing sanitation and disinfection technology to minimize microbial contamination risk to both human and non-human health.

For more information including full biographies of the SailSAFE Global Health and Wellness Council please visit: SailSAFE Global Health and Wellness Council

For more information on the Company’s SailSAFE health and safety program please visit http://www.nclhltd.com/Health-and-Safety.

About Norwegian Cruise Line Holdings Ltd.

Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) is a leading global cruise company which operates the Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises brands. With a combined fleet of 28 ships with approximately 60,000 berths, these brands offer itineraries to more than 490 destinations worldwide. The Company has nine additional ships scheduled for delivery through 2027, comprising of approximately 24,000 berths.

About SailSAFE

Norwegian Cruise Line Holdings Ltd. established its SailSAFE health and safety program in response to the unique challenges of the COVID-19 global pandemic to protect guests, crew and communities visited. SailSAFE is a robust and comprehensive health and safety strategy with new and enhanced protocols to create multiple layers of protection against COVID-19. This science-backed plan for a safe and healthy return to cruising was developed in conjunction with a diverse group of globally recognized experts and will be continuously improved and refined using the best available science and technology.

About the SailSAFE Global Health and Wellness Council

The SailSAFE Global Health and Wellness Council (“Council”) was established by Norwegian Cruise Line Holdings Ltd. to provide expert advice on the implementation, compliance with and continuous improvement of the Company’s SailSAFE health and safety program. The Council will complement the work of the Healthy Sail Panel and continuously evaluate and identify ways to improve health and safety standards after cruise voyages resume, utilizing the best technologies and information available. The Council is cross-functional, diverse and extensively experienced, comprised of six experts at the forefront of their fields and led by Chairman of the Council, Dr. Scott Gottlieb, former commissioner of the U.S. Food and Drug Administration.

About the Healthy Sail Panel

Norwegian Cruise Line Holdings Ltd. in collaboration with Royal Caribbean Group established the Healthy Sail Panel (“HSP”), a group of 11 leading experts to help inform the cruise industry in the development of new and enhanced cruise health and safety standards in response to the global COVID-19 pandemic. The HSP, co-chaired by Dr. Scott Gottlieb, former commissioner of the U.S. Food and Drug Administration and Governor Mike Leavitt, former Secretary of the U.S. Department of Health and Human Services, consists of globally recognized experts from various disciplines, including public health, infectious disease, biosecurity, hospitality and maritime operations. The panel’s work, including detailed recommendations across five key areas of focus, is informing the Company’s health and safety protocols and has been widely shared with the cruise industry and open to any other industry that could benefit from the HSP’s scientific and medical insights.

Cautionary Statement Concerning Forward-Looking Statements

Some of the statements, estimates or projections contained in this release are “forward-looking statements” within the meaning of the U.S. federal securities laws intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this release, including, without limitation, those regarding our business strategy, financial position, results of operations, plans, prospects, actions taken or strategies being considered with respect to our liquidity position, valuation and appraisals of our assets and objectives of management for future operations (including those regarding expected fleet additions, our voluntary suspension, our ability to weather the impacts of the COVID-19 pandemic and the length of time we can withstand a suspension of voyages, our expectations regarding the resumption of cruise voyages and the timing for such resumption of cruise voyages, the implementation of and effectiveness of our health and safety protocols, operational position, demand for voyages, financing opportunities and extensions, and future cost mitigation and cash conservation efforts and efforts to reduce operating expenses and capital expenditures) are forward-looking statements. Many, but not all, of these statements can be found by looking for words like “expect,” “anticipate,” “goal,” “project,” “plan,” “believe,” “seek,” “will,” “may,” “forecast,” “estimate,” “intend,” “future” and similar words. Forward-looking statements do not guarantee future performance and may involve risks, uncertainties and other factors which could cause our actual results, performance or achievements to differ materially from the future results, performance or achievements expressed or implied in those forward-looking statements. Examples of these risks, uncertainties and other factors include, but are not limited to the impact of: the spread of epidemics, pandemics and viral outbreaks and specifically, the COVID-19 pandemic, including its effect on the ability or desire of people to travel (including on cruises), which are expected to continue to adversely impact our results, operations, outlook, plans, goals, growth, reputation, cash flows, liquidity, demand for voyages and share price; our ability to comply with the CDC’s Framework for Conditional Sailing Order and any additional or future regulatory restrictions on our operations and to otherwise develop enhanced health and safety protocols to adapt to the pandemic’s unique challenges once operations resume and to otherwise safely resume our operations when conditions allow; coordination and cooperation with the CDC, the federal government and global public health authorities to take precautions to protect the health, safety and security of guests, crew and the communities visited and the implementation of any such precautions; our ability to work with lenders and others or otherwise pursue options to defer, renegotiate or refinance our existing debt profile, near-term debt amortization, newbuild related payments and other obligations and to work with credit card processors to satisfy current or potential future demands for collateral on cash advanced from customers relating to future cruises; our future need for additional financing, which may not be available on favorable terms, or at all, and may be dilutive to existing shareholders; our indebtedness and restrictions in the agreements governing our indebtedness that require us to maintain minimum levels of liquidity and otherwise limit our flexibility in operating our business, including the significant portion of assets that are collateral under these agreements; the accuracy of any appraisals of our assets as a result of the impact of COVID-19 or otherwise; our success in reducing operating expenses and capital expenditures and the impact of any such reductions; our guests’ election to take cash refunds in lieu of future cruise credits or the continuation of any trends relating to such election; trends in, or changes to, future bookings and our ability to take future reservations and receive deposits related thereto; the unavailability of ports of call; future increases in the price of, or major changes or reduction in, commercial airline services; adverse events impacting the security of travel, such as terrorist acts, armed conflict and threats thereof, acts of piracy, and other international events; adverse incidents involving cruise ships; adverse general economic and related factors, such as fluctuating or increasing levels of unemployment, underemployment and the volatility of fuel prices, declines in the securities and real estate markets, and perceptions of these conditions that decrease the level of disposable income of consumers or consumer confidence; any further impairment of our trademarks, trade names or goodwill; breaches in data security or other disturbances to our information technology and other networks or our actual or perceived failure to comply with requirements regarding data privacy and protection; changes in fuel prices and the type of fuel we are permitted to use and/or other cruise operating costs; mechanical malfunctions and repairs, delays in our shipbuilding program, maintenance and refurbishments and the consolidation of qualified shipyard facilities; the risks and increased costs associated with operating internationally; fluctuations in foreign currency exchange rates; overcapacity in key markets or globally; our expansion into and investments in new markets; our inability to obtain adequate insurance coverage; pending or threatened litigation, investigations and enforcement actions; volatility and disruptions in the global credit and financial markets, which may adversely affect our ability to borrow and could increase our counterparty credit risks, including those under our credit facilities, derivatives, contingent obligations, insurance contracts and new ship progress payment guarantees; our inability to recruit or retain qualified personnel or the loss of key personnel or employee relations issues; our reliance on third parties to provide hotel management services for certain ships and certain other services; our inability to keep pace with developments in technology; changes involving the tax and environmental regulatory regimes in which we operate; and other factors set forth under “Risk Factors” in our most recently filed Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Additionally, many of these risks and uncertainties are currently amplified by and will continue to be amplified by, or in the future may be amplified by, the COVID-19 pandemic. It is not possible to predict or identify all such risks. There may be additional risks that we consider immaterial or which are unknown. The above examples are not exhaustive and new risks emerge from time to time. Such forward-looking statements are based on our current beliefs, assumptions, expectations, estimates and projections regarding our present and future business strategies and the environment in which we expect to operate in the future. These forward-looking statements speak only as of the date made. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained herein to reflect any change in our expectations with regard thereto or any change of events, conditions or circumstances on which any such statement was based, except as required by law.

Investor Relations & Media Contact

Andrea DeMarco
(305) 468-2339
[email protected]

Jessica John
(786) 913-2902

A PDF accompanying this announcement is available at:
http://ml.globenewswire.com/Resource/Download/325d1c72-d379-46f1-93fd-c012c374d973

 

TORONTO, April 06, 2021 (GLOBE NEWSWIRE) — Medivolve Inc. (“Medivolve”) (NEO:MEDV; OTC:COPRF; FRA:4NC) is pleased to provide a sales update for its wholly owned subsidiary, Collection Sites, LLC. During the month of March, Collection Sites realized the sale of 20,574 tests at an average selling price of $99 per test across its network. Approximately 59% of the sales were insurance pay, with the balance being cash sales. The Company continued to see the strongest demand for antigen tests, followed by antibody and then PCR tests.

“March was another solid month of sales for Collection Sites with over 20,000 tests conducted across our network. Compared to a more substantial drop from January to February, we saw a steady state with testing demand remaining relatively stable over the month,” commented Medivolve CEO Doug Sommerville. “As we continue to increase our offerings, including our new immunity tests, the AditxtScore, and through participation in government testing programs such as HRSA, we believe we can grow our testing numbers.”

Upcoming Corporate Webinar

Medivolve is pleased to announce it is hosting a Corporate Update webinar, on Thursday, April 15 at 1 pm ET that will provide investors with an update on the Company’s recent business developments.

Registration Link:



https://us02web.zoom.us/webinar/register/WN_pRyhGijjSgCGKKsE90lMPQ

Specifically, the webinar will feature Medivolve CEO Doug Sommerville as he provides an overview on the Company’s recent developments, including March sales numbers and new testing services that are being offered. Representatives from the maker of the AditxtScore COVID-19 immunity test will also join the webinar to share more details on their innovative technology. Collection Sites intends on leveraging its network of sites and large customer database to market these new services and launch a series of mobile clinics.

About the Collection Sites

The pop-up labs will be managed by Las Vegas based company Collection Sites, LLC and powered by Alcala Testing and Analysis Services, a CLIA-licensed laboratory based in San Diego, California. Appointments and payments will be handled through an online portal www.testbeforeyougo.com.

The key to flattening the curve is to increase testing.

The testing centers will offer convenient access to rapid antibody and antigen (pending availability) tests – which take 8-10 minutes to administer and provide results within 24 hours. The sites also offer regular RT-PCR. All tests can be administered with insurance coverage options. The tests results can be communicated via text or email and can be accompanied with a certificate of good health via a HIPAA-compliant smartphone application.

For more information about the pop-up lab, the available sites and services visit 


www.testbeforeyougo.com


.

About Medivolve Inc.

Medivolve Inc.
(NEO:MEDV; OTC:COPRF; FRA:4NC) seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, Medivolve offers investors a diversified investment in the COVID-19 medical space across three areas; prevention, detection, and treatment.

Medivolve has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space. This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.

Medivolve’s primary focus is to provide convenient and assessable medical services for testing of the COVID-19 virus to help combat the pandemic. This is achieved largely through two acquisitions: 100% of Collection Sites, LLC and 28% of Colombian Sanaty IPS. Collection Sites is setting up a series of COVID-19 testing sites across the United States with appointments and payments will be handled through the online portal www.testbeforeyougo.com. Sanaty is setting up a series of full-service medical clinics offering a complete COVID-19 testing solution.

For additional information, please contact:

Doug Sommerville, CEO
[email protected]

For investing inquiries please contact:
[email protected]

For US media enquires please contact:
Veronica Welch
[email protected]

Cautionary Note Regarding Forward-looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to sales results; the proposed roll-out of business testing; the Company’s expansion into telehealth; projected timelines for testing results; projected revenues from the testing; the pursuit by Medivolve of investment opportunities; and the merits or potential returns of any such investments. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

WASHINGTON, April 06, 2021 (GLOBE NEWSWIRE) — Project Learning Tree^® (PLT) released a new curriculum guide today to engage kindergarten through grade 8 students in exploring their environment. Project Learning Tree is a long-established, award-winning environmental education program that uses trees and forests as windows on the world to advance environmental literacy, stewardship, and pathways to green careers. The guide includes fifty field-tested, hands-on activities that integrate investigations of nature with science, math, English language arts, and social studies. It incorporates outdoor education and connects youth to nature which has many proven benefits.

Educators can obtain a copy of PLT’s Explore Your Environment: K-8 Activity Guide directly from PLT’s Shop or by attending a local PLT professional development workshop conducted by PLT’s 50-state network of 75 coordinators and 1,000 facilitators across the country. This new, cutting-edge resource for educators offers robust, real-world learning experiences for students designed to bolster STEM (science, technology, engineering and math) learning, promote civic engagement, and help young people acquire the skills they’ll need to be creative problem solvers. To further support educators, each PLT activity displays explicit connections to practices and concepts mandated by the Next Generation Science Standards (NGSS), Common Core State Standards (CCSS) for English Language Arts and Mathematics, and College, Career, and Civic Life Framework for Social Studies (C3). The activities develop students’ critical thinking skills as they participate in hands-on learning, debate real-life environmental decisions, and engage with their community in action projects.

“The guide is fresh, user-friendly, and works indoors and outdoors, in classrooms and nonformal settings, in urban, suburban, and rural settings” says Jaclyn Stallard, PLT’s Director of Curriculum. “Educators can easily integrate the activities into their existing curriculum or other programming to actively engage students in learning about both the natural world and the built environment. Every activity in the guide suggests ways to take student learning outside, which has only increased in importance to many parents and educators over the last year due to Covid-19.”

PLT is an initiative of the Sustainable Forestry Initiative (SFI). Since becoming part of SFI in 2017, PLT has won two Learning^® Magazine Teachers’ Choice^SM Awards including for its Energy in Ecosystems curriculum for grades 3-5 in 2019, and its Carbon & Climate curriculum in 2020.

“Exposure to nature has many proven benefits for physical and mental health and learning outdoors can enhance academic achievement,” says Jessica Kaknevicius, Vice President of Education for SFI. “Engaging students in exploring their environment provides important opportunities for youth to become engaged in real world issues. From the earliest grades on up, they see the relevance of their classroom studies and acquire the skills needed for green careers in the 21st century workplace.”

About Project Learning Tree

PLT is an award-winning environmental education program that advances environmental literacy, stewardship and career pathways using trees and forests as windows on the world. PLT teaches kids how to think, not what to think about the environment and supports getting youth into nature in ways that are meaningful, that inspire them to become environmental stewards and future conservation leaders, and that introduce them to green careers. PLT is an initiative of the Sustainable Forestry Initiative. Learn more: plt.org.

About the Sustainable Forestry Initiative

SFI advances sustainability through forest-focused collaborations. SFI is an independent, non-profit organization that leverages four interconnected pillars of work: standards, conservation, community, and education. SFI works with the forest sector, conservation groups, academics, researchers, brand owners, resource professionals, landowners, educators, local communities, Indigenous Peoples, and governments. SFI collaborates with its network to leverage SFI-certified forests and products as powerful tools to help solve sustainability challenges such as climate action, conservation of biodiversity, education of future generations, and sustainable economic development. Learn more: forests.org.

Media Contact:

Vanessa Bullwinkle
Sr. Director, Communications and Marketing
Project Learning Tree
Sustainable Forestry Initiative
202-765-3726 / [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9bb25f36-bba7-4973-b5fb-95c6f65c9b91

 

VANCOUVER, British Columbia, April 06, 2021 (GLOBE NEWSWIRE) — WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that it has received prepayment of approximately C$954,248 (3,000,000 PLN) from the Polish National Center for Research and Development (“NCRD”) for the further development of Berubicin, the Company’s drug candidate targeting glioblastoma multiforme (“GBM”). The funds received are from a total C$7.4 million grant awarded to WPD, and will be used for two clinical studies, planned to be implemented under the project: “New approach to glioblastoma treatment addressing the critical unmet medical need”. The grant was made by the European Union, under the Smart Growth Operational Program 2014-2020. The approved prepayment for WPD’s continued advancements of the Berubicin drug candidate further validates WPD’s scientific development strategy and government support in doing so and helps WPD fulfill requirements under its sublicense agreement with CNS Pharmaceuticals, Inc.

As a part of the Berubicin development strategy, WPD has requested scientific advice on pre-clinical and clinical development from the European Medicines Agency (“EMA”). On March 24, 2021, WPD attended a Pre-Submission Meeting with EMA experts during which useful information was provided on the preparation of documentation for the upcoming meeting with the Scientific Advice Working Party (“SAWP”) of EMA.

EMA allows medicinal drug developers to request scientific advice during initial drug development, before submission of a marketing authorization application. EMA established SWAP for the purpose of providing scientific advice to applicants by providing advice on quality aspects, methodology and pre-clinical and clinical development of drugs being developed, based on documentation provided by the developer.

Mariusz Olejniczak, CEO of WPD commented, “We are very excited with the results of our Pre-Submission Meeting with the EMA Experts as this helps us plan our Berubicin development program. As a result of our discussion with the EMA experts, we have decided to apply for orphan designation for Berubicin. The EU offers a range of incentives to encourage the development of designated orphan medicines, to facilitate the development and authorization of medicines for rare diseases. Drugs in development that obtain orphan designation benefit from protocol assistance, scientific advice specific for designated orphan medicines, and market exclusivity once the medicine is on the market. Fee reductions may also available.”

About WPD Pharmaceuticals

WPD is a biotechnology research and development company with a focus on oncology and virology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has licensed in certain countries 10 novel drug candidates with 4 that are in clinical development stage. These drug candidates were researched at medical institutions, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things.  The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes for most compounds 30 countries in Europe and Asia, including Russia.

On Behalf of the Board

‘Mariusz
Olejniczak’

Mariusz Olejniczak
CEO, WDP Pharmaceuticals

Contact:

Investor Relations
Email: [email protected] 
Tel: 604-428-7050
Web: www.wpdpharmaceuticals.com 

Cautionary Statements:

Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

This press release contains forward-looking statements. Forward-looking statements are statements that contemplate activities, events or developments that the Company anticipates will or may occur in the future. Forward-looking statements in this press release include that we can access the remainder of our NCRD grants, that our drug Glioma could attain EU designated orphan status and that WPD’s drugs could be developed into novel treatments for cancer. These forward-looking statements reflect the Company’s current expectations based on information currently available to management and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those projected. Factors which may prevent the forward looking statement from being realized is that competitors or others may successfully challenge a granted patent and the patent could be rendered void; that we are unable to raise sufficient funding for our research; that we may not meet the requirements to receive the grants awarded or orphan status sought; that our drugs don’t provide positive treatment, or if they do, the side effects are damaging; competitors may develop better or cheaper drugs; and we may be unable to obtain regulatory approval for any drugs we develop. Readers should refer to the risk disclosure included from time-to-time in the documents the Company files on SEDAR, available at www.sedar.com. Although the Company believes that the assumptions inherent in these forward-looking statements are reasonable, they are not guarantees of future performance and, accordingly, they should not be relied upon and there can be no assurance that any of them will prove to be accurate. Finally, these forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update them except as required by applicable law.

Global players commit to collaborate on building a hydrogen economy and supply chain in India

Chart Industries and Reliance Industries to act as steering group co-leads

Industry players to help develop hydrogen production and storage, industrial and transport use-cases

NEW DELHI, India and MUMBAI, India, April 06, 2021 (GLOBE NEWSWIRE) — Global energy and industrial majors have come together to form a new energy transition coalition, the India H2 Alliance (“IH2A”), focussed on commercializing hydrogen technologies and systems to build net-zero carbon pathways in India. The India H2 Alliance will work together to build the hydrogen economy and supply chain in India and help develop blue and green hydrogen production and storage as well as build hydrogen-use industrial clusters and transport use-cases with hydrogen-powered fuel cells. The India H2 Alliance will focus on industrial clusters, specifically steel, refineries, fertilizer, cement, ports and logistics; as well as heavy-duty transport use cases and the establishment of standards for storage and transport hydrogen in pressurized and liquified form.

The India H2 Alliance will work with the government on five areas – (1) develop a National Hydrogen Policy and Roadmap 2021-2030, (2) creation of a National H2 Taskforce and Mission in a public-private partnership format, (3) identify National Large H2 Demonstration-Stage Projects, (4) help create a national India H2 Fund and (5) create hydrogen-linked capacity covering hydrogen production, storage and distribution, industrial use-cases, transport use-cases and standards.

Commenting on the launch of the India H2 Alliance, Jillian Evanko, CEO and President of Chart Industries (NYSE: GTLS) and founding member, said, “Proactive industry collaboration with the government is key to creating a hydrogen economy in India. Through India H2 Alliance, we will bring best-in-class hydrogen technology, equipment and know-how to create a hydrogen supply chain in India, and in many cases, ‘Made in India’. By prioritizing national hydrogen demonstration projects, innovations to further reduce the cost of hydrogen will become prominent, locally.”

Commenting on the focus of the India H2 Alliance, Anurag Pandey, R&D Team Lead, Reliance Industries Limited, said, “India needs to identify and execute large-scale hydrogen demonstration projects if it wants to be part of the global supply chain for hydrogen. Beyond R&D pilots, India needs ‘hydrogen-valley’ style national initiatives across a region like a high-traffic industrial freight corridor, with multiple use-cases. Such hydrogen-related systems projects are strategic for India’s energy transition plans, linking closely with renewables and battery-technology. These require multiple industry players to come together and form consortia to implement such projects. IH2A will take the lead on such initiatives.”

The India H2 Alliance will have a panel of hydrogen experts and a IH2A secretariat to support member companies.   The IH2A Secretariat will be run by consulting firm FTI Consulting.

About India H2 Alliance (IH2A)

The India H2 Alliance is an industry coalition of global and Indian companies committed to the creation of a hydrogen value-chain and economy in India. IH2A intends to collaborate with private sector partners, the government and the public to ensure that costs of hydrogen production are brought down, a local supply chain for hydrogen and related applications grows and India is able to achieve its net-zero carbon ambitions by developing a hydrogen economy that complements its national renewable energy and EV/battery-technology plans. More information on IH2A and its activities, will shortly be available at www.IH2A.com.

Contact


Sabrina Sidhu
FTI Consulting
M: +91 9875981777
[email protected]

Pragya Gupta
FTI Consulting
M: +91 8130260865
[email protected]

PAI Acquired for $213 Million, Expected to Generate Approximately $30 Million of Adjusted EBITDA in 2021
Provides Full Range of Managed Services for Approximately 100,000 ATMs
Adds Management Depth and Technology, Expands Brink’s ATM Service Capabilities
Strengthens “Strategy 2.3” Platform in North America

RICHMOND, Va., April 06, 2021 (GLOBE NEWSWIRE) — The Brink’s Company (NYSE: BCO), the global leader in total cash management, route-based secure logistics and payment solutions, today announced its acquisition of PAI, Inc., the largest privately-held provider of ATM services in the U.S., for $213 million. On a current full-year basis, PAI is expected to generate revenue of approximately $320 million and adjusted EBITDA of approximately $30 million. Given the acquisition’s closing date of April 1, PAI is expected to add approximately $240 million of revenue and $22 million of adjusted EBITDA to the company’s 2021 results and is expected to be accretive this year. Based in its new headquarters in Dallas, Texas, PAI employs 225 people across three major U.S. locations and another 12 field locations. The acquisition was financed using available cash and the company’s existing credit facility.

PAI offers a full range of managed services and tools for ATM owner-operators and PAI-owned ATMs, including its SaaS-based technology platform (AMP+), which maximizes ATM network performance and provides real-time visibility. PAI’s field services are built around its VTS (Vantage Technical Services) cash management and maintenance solution for ATM devices. Core services include remote device management, transaction processing, bank sponsorship, technology updates and product development. PAI maintains its own software development and services team in Billings, Montana.

Strategic Rationale

A primary goal of Brink’s Strategy 2.3 is to offer ATM solutions integrated with other Brink’s solutions to provide complete, end-to-end cash management. PAI provides Brink’s with a platform of proprietary ATM services and more than 100,000 ATM service locations in the U.S., accelerating its execution of Strategy 2.3 initiatives in North America. In Europe, Brink’s has entered into agreements to take full ownership and provide managed services to financial institutions for more than 11,000 ATMs. With PAI’s capabilities, Brink’s will offer a more complete and technology-rich range of bundled ATM services to U.S. retailers, banks and credit unions through multi-year service contracts that generate recurring revenue streams.

Doug Pertz, president and CEO of Brink’s, said: “Strategy 2.3 is all about delivering digital solutions that make full-service ATM management and outsourcing easier and more efficient for retailers, financial institutions and consumers. PAI brings a strong management team led by David Dove, robust technology and a scalable, asset-light business model that complements our existing capabilities.

“With PAI’s proprietary technology, Brink’s is now uniquely positioned to offer U.S. customers a complete range of ATM services, including full-service outsourcing, which increases the value of their ATM networks. In addition, PAI currently offers Bitcoin purchasing at a select number of ATM locations.

“With PAI, Brink’s now offers total cash management solutions across the cash ecosystem. In addition, the acquisition provides cross-selling opportunities for PAI and Brink’s. The acquisition of PAI demonstrates our strong commitment to transforming Brink’s by offering comprehensive and innovative solutions that connect cash management to the digital economy.

“We expect significant revenue synergies and some operational cost synergies from the acquisition over the next several years, and look forward to further discussing PAI’s business and strategy when we release first-quarter earnings.”

David Dove, CEO of PAI, said: “We are exceptionally happy to join Brink’s and look forward to accelerating its execution of Strategy 2.3 by building additional recurring and transaction-based revenue streams in the U.S. Our mission is to make the management of ATMs easy and efficient, and by extension, provide a reliable way to keep cash within arm’s reach for consumers. We see this as critically important to the U.S. economy given the continued increase of cash in circulation. By way of example, in the first quarter, cash transactions from our fleet of 100,000 ATMs increased more than 15% on a ‘same store’ basis and more than 30% organically versus the year-ago quarter. In addition, total cash dispensed from our fleet increased more than 30% on a ‘same store’ basis and more than 50% organically versus the year-ago quarter. We expect our business platform, led by ATM portfolio management technology and VTS solutions, to scale nicely across the Brink’s footprint. Our management team looks forward to making a substantial contribution to the growth and transformation of Brink’s.”

About The Brink’s Company

The Brink’s Company (NYSE:BCO) is the global leader in total cash management, route-based secure logistics and payment solutions including cash-in-transit, ATM services, cash management services (including vault outsourcing, money processing and intelligent safe services), and international transportation of valuables. Our customers include financial institutions, retailers, government agencies, mints, jewelers and other commercial operations. Our global network of operations in 53 countries serves customers in more than 100 countries. For more information, please visit our website at www.brinks.com or call 804-289-9709.

About PAI

PAI is the nation’s largest, privately held provider of ATM portfolio management tools and services for more than 100,000 ATMs, including transaction processing, bank sponsorship, maintenance, cash-in-transit (CIT) servicing and AMP+, the company’s market-leading technology. PAI’s portfolio management tools offer the most visibility and control to maximize ATM portfolio effectiveness and profitability. For more information, please visit gopai.com.

Forward-Looking Statements

This release contains forward-looking information. Words such as “anticipate,” “assume,” “estimate,” “expect,” “target” “project,” “predict,” “intend,” “plan,” “believe,” “potential,” “may,” “should” and similar expressions may identify forward-looking information. Forward-looking information in these materials includes, but is not limited to: future results of the PAI business and the impact on Brink’s results, acquisition-related synergies, and the addition of ATM customers in other markets. Forward-looking information in this document is subject to known and unknown risks, uncertainties and contingencies, which are difficult to predict or quantify, and which could cause actual results, performance or achievements to differ materially from those that are anticipated.

Forward-looking information in this document is subject to known and unknown risks, uncertainties and contingencies, which are difficult to predict or quantify, and which could cause actual results, performance or achievements to differ materially from those that are anticipated. These risks, uncertainties and contingencies, many of which are beyond our control, include, but are not limited to: our ability to improve profitability and execute further cost and operational improvement and efficiencies in our core businesses; our ability to improve service levels and quality in our core businesses; market volatility and commodity price fluctuations; seasonality, pricing and other competitive industry factors; investment in information technology (“IT”) and its impact on revenue and profit growth; our ability to maintain an effective IT infrastructure and safeguard confidential information; our ability to effectively develop and implement solutions for our customers; risks associated with operating in foreign countries, including changing political, labor and economic conditions, regulatory issues (including the imposition of international sanctions, including by the U.S. government), currency restrictions and devaluations, restrictions on and cost of repatriating earnings and capital, impact on the Company’s financial results as a result of jurisdictions determined to be highly inflationary, and restrictive government actions, including nationalization; labor issues, including negotiations with organized labor and work stoppages; pandemics (including the ongoing COVID-19 pandemic and related impact to and restrictions on the actions of businesses and consumers, including suppliers and customers), acts of terrorism, strikes or other extraordinary events that negatively affect global or regional cash commerce;  anticipated cash needs in light of our current liquidity position and the impact of COVID-19 on our liquidity; the strength of the U.S. dollar relative to foreign currencies and foreign currency exchange rates; our ability to identify, evaluate and complete acquisitions and other strategic transactions and to successfully integrate acquired companies; costs related to dispositions and product or market exits; our ability to obtain appropriate insurance coverage, positions taken by insurers relative to claims and the financial condition of insurers; safety and security performance and loss experience; employee and environmental liabilities in connection with former coal operations, including black lung claims; the impact of the Patient Protection and Affordable Care Act on legacy liabilities and ongoing operations; funding requirements, accounting treatment, and investment performance of our pension plans, the VEBA and other employee benefits; changes to estimated liabilities and assets in actuarial assumptions; the nature of hedging relationships and counterparty risk; access to the capital and credit markets; our ability to realize deferred tax assets; the outcome of pending and future claims, litigation, and administrative proceedings; public perception of our business, reputation and brand; changes in estimates and assumptions underlying critical accounting policies; the promulgation and adoption of new accounting standards, new government regulations and interpretation of existing standards and regulations.

This list of risks, uncertainties and contingencies is not intended to be exhaustive. Additional factors that could cause our results to differ materially from those described in the forward-looking statements can be found under “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the period ended December 31, 2020 and in our other public filings with the Securities and Exchange Commission. The forward-looking information included in this document is representative only as of the date of this document and The Brink’s Company undertakes no obligation to update any information contained in this document.

Contact: Investor Relations
804.289.9709

 

Dallas, April 06, 2021 (GLOBE NEWSWIRE) — Thryv Holdings, Inc. (NASDAQ:THRY), the provider of Thryv^® software, the end-to-end customer experience platform built for growing small business, has been named a leader in multiple categories in the newly released G2 Spring 2021 Reports. G2 is an online tech marketplace where technology users can discover and review technology and make informed decisions when purchasing software. 

Thryv earned 14 G2 Leader awards, breaking last quarter’s record for most honors in a single quarter. The Leader distinction is G2’s highest level award, followed by the High Performers, Contenders, and Niche player levels. Thryv was named a Leader for Small Business for the sixth quarter in a row, and an overall Leader among competitors across all categories. 

For the Spring quarter, G2 named Thryv the No. 3 payment gateway choice among small businesses, narrowly behind No. 2 Apple Pay. PayPal leads the category. 

“This is remarkable progress for Thryv and our payment processing service, ThryvPay, which we launched in late 2020,” said Ryan Cantor, Thryv’s VP of Product and Marketing. “We designed ThryvPay specifically for service-based businesses, and it’s clearly resonating that they needed a payments option tailored for them. We are delighted to see how ThryvPay and all of the other flexible payment features inside Thryv are meeting the needs of small business owners nationwide.” 

In addition to payments, Thryv provides a multitude of functionality in its platform, such as a newly enhanced and verticalized CRM, marketing automation, online scheduling, relationship management and more. Leading in these categories within G2 has once again earned Thryv’s place as a Momentum Leader for the third quarter in a row. 

Thryv added two new G2 Leader categories this quarter: Easiest to Use for Small Business and Best Support for Small Business. Reviewers repeatedly mentioned how these two areas set Thryv apart. 

“Thryv has catapulted my business to a wider audience. It’s made on-the-go invoicing and receiving payments a snap, and the entire team has been absolutely delightful to work with,” said verified Thryv user and G2 reviewer, Gina Surrette, who owns GMS Inspection Services. “They walk me through the things I don’t understand and help set me up for success across the board. 

“I truly can’t say enough about every person I have interacted with so far!” 

Additional G2 Spring Report 2021 Leadership Awards for Thryv include:

• Thryv was named a Leader for Overall Best Support for the second quarter in a row, and Best Support for Small Business for the first time.
• G2 named Thryv Overall Best Estimated ROI for a second quarter in a row.
• Thryv had the Highest User Adoption for Small Business for the third quarter in a row.
• Thryv was a Leader in Overall Highest User Adoption for  the second time.
• Thryv Small Business users were Most Likely to Recommend Thryv for the third quarter in a row.
• Thryv’s users Overall were Most Likely to Recommend.
• For the fourth straight quarter, users said Thryv had the Easiest Set-up among Small Businesses and Overall.
• Also for the fourth quarter in a row, Small Business users recognized that Thryv had the Easiest to Administer Software.
• And new this quarter, Small Business users said Thryv is the Easiest to Use.

“Because the G2 awards are solely determined by the reviews, sentiment and commentary from verified users, we consider these to be our highest honors of the year,” Cantor says. “We realize small business owners are busy and not always familiar with using software. This is why we provide free, unlimited support to get them up-to-speed quickly, so they can optimize the software and successfully manage their business. This is a game changer for Thryv and throughout the industry. And clearly, it shows.”

 

About Thryv Holdings, Inc.

Thryv Holdings, Inc. owns the easy-to-use Thryv® end-to-end customer experience software built for growing small to medium sized businesses (SMBs) that helps over 40,000 SaaS clients with the daily demands of running a business. With Thryv®, SMBs can get the job, manage the job and get credit. Thryv’s award-winning platform provides modernized business functions, allowing SMBs to reach more customers, stay organized, get paid faster and generate reviews. These functions include building a digital customer database, automated marketing through email and text, updating business listings across the internet, scheduling online appointments, sending notifications and reminders, managing ratings and reviews, generating estimates and invoices, and processing payments.

Thryv supports franchise operators and multi-location business owners with Hub by Thryv™, a software console that enables businesses managers to oversee their operations using the Thryv® software.

Thryv also connects local businesses to consumer services through our search, display and social media management products, our print directories featuring The Real Yellow Pages® tagline, and our local search portals, which operate under the DexKnows.com®, Superpages.com® and Yellowpages.com URLs and reach some 35 million monthly visitors. For more information about the company, visit thryv.com. 

Thryv delivers business services to more than 400,000 SMBs worldwide that enable these SMBs to compete and win in today’s economy.    

On March 1, 2021, Thryv announced it closed the acquisition of Sensis, Australia’s leading digital, marketing and directory services provider, which helps Australians connect and engage through its leading platforms, digital consumer businesses (Yellow, White Pages, True Local and Whereis), search engine marketing and optimization services, website products, social, data and mapping solutions, and through its digital agency Found. Sensis is also Australia’s largest print directory publisher including the Yellow and White Pages.

Headquartered in Melbourne, Sensis has a sales presence in all states and territories across Australia. 

Media Contact:  

Paige Blankenship

Thryv, Inc.

972.453.3012                                                                         

[email protected]

 

Investor Contacts:   

Cameron Lessard 

Thryv, Inc.    

214.773.7022 

[email protected]   

 

KJ Christopher  

Thryv, Inc.    

972.453.7068  

[email protected]  

 

###

 

Paige Blankenship
Thryv, Inc.
972.453.3012
[email protected]

• Revenue of CAD$2.8 million – an increase of 65% from CAD$1.7 million for the same time last year

• Gross margin increases to 41% vs 16% last year same time

• Adjusted EBITDA of CAD$92,481

• Financial results are not inclusive of the current in-progress move to the Concord, CA facility, which is more than double the size, as well as the 2
  
  ^nd
  
  automated pre-roll machine which is expected to arrive in 2021 Calendar Q2.
  

VANCOUVER, British Columbia, April 06, 2021 (GLOBE NEWSWIRE) — Icanic Brands Company, Inc. (CSE: ICAN, OTCQB: ICNAF) (“Icanic Brands” or the “Company”), a multi-state brand operator of premium Cannabis brands in California and Nevada, today reports its financial results for the period ended January 31^st, 2021. All currency references used in this news release are in Canadian currency unless otherwise noted.

Management Commentary

Mr. Brandon Kou, CEO of Icanic commented, “I am really proud of what the entire team accomplished even during this global pandemic. We were able to grow revenues significantly from the same time last year while improving our gross margin dramatically. Our plan was always to build a sustainable foundation with a superior gross margin profile in the calendar year of 2020 and these quarterly results show that we are well on our way.  As we continue to look to 2021, we will no doubt turn our attention to growth both organically through our leading brands as well as taking advantage of opportunities in the market that will help us accomplish our goals quicker.”

Summary of 2021 Developments:

• Icanic Brands sees 65% increase in revenue for period ended January 31^st, 2021, from the same time period last year
• The company received over $1,000,000 cash injection via exercise of warrants
• Mr. Mark Smith joined Icanic Brands as Executive Chairman

About Icanic Brands Company, Inc.

Icanic Brands Company, Inc. is a leading cannabis branded products manufacturer based in California & Nevada, the largest and most competitive cannabis markets in the world. The company’s mission is to make cannabis safe and approachable – that starts with manufacturing high-quality products delivering consistent experiences.

For more information, please visit the company’s website at: www.icaninc.com.

About Ganja Gold
Ganja Gold, Inc., a wholly-owned subsidiary of Icanic Brands Company, Inc. (CSE: ICAN, OTCQB: ICNAF), is the premier brand of infused pre-rolls in the state. Ganja Gold focuses on using only the best available flower and concentrates with state of the art proprietary technology to create connoisseur level pre-rolls unseen in the marketplace. With our flagship Tarantula™, Ganja Gold continues to set the bar in quality and experience.

For more information about Ganja Gold, visit their website at www.ganjagold.com

ICANIC BRANDS COMPANY INC.
Per: “Brandon Kou”
Chief Executive Officer

For further information about Icanic Brands, please contact the Company at:

Email: [email protected]

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.